Princess Alexandra Hospital - Neurology Movement Disorder Research Team(6.9 mi away)Contact
+78 other location
impulse control disorder
The purpose of this study is to evaluate the clinical efficacy, safety and pharmacokinetics
(PK) of 2 fixed doses of tavapadon and placebo in participants with early Parkinson's Disease.
An estimated total of 522 eligible subjects with early Parkinson's Disease, will be randomized to 3 treatment groups. Subjects will be randomized in a 1:1:1 ratio to receive tavapadon 5 mg, tavapadon 15 mg or placebo. Each subject will participate in the study for approximately 35 weeks including a 30 day screening period, 27 week treatment period, and 4 week follow-up period.
Subjects may continue to an optional open-label extension period for one year.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.